General description
Medicine type
Chemical agent
EML status history
First added in 2019
(TRS
1021)
for
Acute myeloid leukaemia with recurrent genetic abnormalities
Therapeutic equivalent for
Wikipedia
Recommendations
Section
Cytotoxic medicines
- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)